Publications en collaboration avec des chercheurs de Centro Nacional de Investigaciones Oncológicas (18)

2022

  1. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

  2. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

    Cancers, Vol. 13, Núm. 3, pp. 1-12

  2. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

  3. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  4. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy

    EBioMedicine, Vol. 53

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3203-3213

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC

    International Journal of Cancer, Vol. 132, Núm. 9, pp. 1986-1995

2009

  1. A gene-alteration profile of human lung cancer cell lines

    Human Mutation, Vol. 30, Núm. 8, pp. 1199-1206

2008

  1. A microRNA DNA methylation signature for human cancer metastasis

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, Núm. 36, pp. 13556-13561

  2. Frequent BRG1/SMARCA4-Inactivating mutations in human lung cancer cell lines

    Human Mutation, Vol. 29, Núm. 5, pp. 617-622

2007

  1. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway

    Neoplasia, Vol. 9, Núm. 10, pp. 840-852

2004

  1. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis

    Laboratory Investigation, Vol. 84, Núm. 8, pp. 999-1012

  2. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene

    Oncogene, Vol. 23, Núm. 22, pp. 4037-4040